Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality?

Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia, Enzo Galligioni

Research output: Contribution to journalArticlepeer-review


The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)1301-1308
Number of pages8
JournalCurrent Drug Targets
Issue number11
Publication statusPublished - Sep 1 2016


  • Abiraterone acetate
  • Cabazitaxel. enzalutamide
  • Castration-resistant prostate cancer
  • Docetaxel
  • First-line
  • Second-line
  • Sequence

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality?'. Together they form a unique fingerprint.

Cite this